QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Pulmonary Embolectomy System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pulmonary Embolectomy System market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Pulmonary Embolectomy System was estimated to be worth US$ 1110 million in 2025 and is projected to reach US$ 1860 million, growing at a CAGR of 7.6% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6695436/pulmonary-embolectomy-system
Pulmonary Embolectomy System Market Summary
1. Definition and Scope
Pulmonary embolectomy systems refer to a category of medical devices designed to remove thrombotic emboli from the pulmonary arteries through percutaneous catheter-based intervention, with the goals of restoring pulmonary blood flow, reducing right ventricular afterload, and improving patient hemodynamic status. Pulmonary embolism is an acute cardiovascular event caused by thrombus obstructing the pulmonary artery or its branches, with a clinical spectrum ranging from asymptomatic embolism to massive embolism with obstructive shock, the latter carrying extremely high short-term mortality.
From a technical pathway perspective, clinically available pulmonary embolectomy systems fall into two main categories. The first is mechanical aspiration thrombectomy systems, which operate by transmitting negative pressure to the thrombus site through a catheter and removing the aspirated thrombus from the body. The second is catheter-directed thrombolysis systems, which deliver thrombolytic medication directly into the thrombus through multi-sideport catheters, maximizing local drug concentration while minimizing systemic bleeding risk.
2. Overall Industry Development
The global pulmonary embolectomy system market is in a rapid growth phase transitioning from mid-stage clinical exploration to large-scale commercial adoption. Market growth is driven by multiple factors including pulmonary embolism epidemiological burden, technological iteration, and accumulating clinical evidence. From a disease burden perspective, pulmonary embolism is the third most common cause of cardiovascular death, behind only myocardial infarction and stroke.
From an industry development stage perspective, the pulmonary embolism interventional treatment field is experiencing a paradigm shift from medication-dominant to catheter intervention priority. Historically, surgical open embolectomy or systemic thrombolysis were the only options for massive pulmonary embolism patients requiring reperfusion therapy. With catheter technology advances, percutaneous catheter embolectomy is increasingly used as a first-line reperfusion strategy.
From a regional competitive landscape perspective, North America currently holds the dominant position, with advantages in clinical guideline currency, reimbursement coverage, and indigenous innovative device company activity. The Asia-Pacific region is widely considered the future growth engine, driven by aging-related venous thromboembolism prevalence rise, expanding interventional cardiology and vascular surgery workforces, and continued investment in standardized pulmonary embolism care systems.
3. Key Development Characteristics
Characteristic One: Technology Iteration Focusing on Balancing Aspiration Efficiency and Bleeding Risk Control.
The core clinical evaluation metric for pulmonary embolectomy systems is balancing thrombus reduction efficiency with procedural safety. Several trends are evident in pursuing higher aspiration efficiency. First is catheter diameter increases and wall structure optimization, though this must be balanced against reduced flexibility. Second is automation evolution from manual to intelligent vacuum pump systems. Third is growing emphasis on distal embolic protection.
Characteristic Two: Clinical Evidence Accumulation Driving Guideline Recommendation Upgrades and Indication Boundary Expansion.
Multiple prospective multicenter single-arm studies and registries have published safety and efficacy data for embolectomy systems in intermediate-high risk pulmonary embolism patients, directly driving clinical guideline updates. Concurrently, the treatment window is expanding from massive pulmonary embolism with shock toward high-risk patients with right ventricular dysfunction but stable blood pressure.
Characteristic Three: Product Strategy Evolving Toward Platformization Plus Differentiation.
Early markets featured single-product strategies. Next-generation manufacturers are pursuing platformization strategies, developing product families suitable for different anatomical scenarios, thrombus burdens, and patient characteristics. Differentiation strategies vary, with some emphasizing ultra-large aspiration lumens, others integrating aspiration with lytic infusion, and others focusing on visualization and navigation enhancement.
Characteristic Four: Clinical Access Cascading from Expert Specialty Centers to Regional General Hospitals.
Pulmonary embolectomy systems are increasingly moving from large academic centers to regional general hospital catheterization laboratories. Key enablers include simplified operational workflows, matured manufacturer training systems, remote proctoring platforms, and supportive reimbursement policies.
4. Favorable Factors for Development
First, the comprehensive disease burden of venous thromboembolism continues to rise globally.
With population aging, rising malignancy incidence, and increasing post-surgical patient volumes, venous thromboembolism incidence remains high and trending upward. This sustained disease burden creates stable end-demand for pulmonary embolectomy systems.
Second, systematic clinical guideline upgrades provide authoritative endorsement.
Multiple authoritative society guidelines have consistently elevated catheter intervention positioning for intermediate-high risk patients. Guideline updates provide clear patient selection criteria, support hospital investment decisions, and accelerate reimbursement policy development.
Third, technology spillover from structural heart and vascular intervention benefits this field.
Advances in large-bore vascular closure devices, catheter navigation systems, and thrombus extraction device design have significantly shortened embolectomy system development cycles and reduced validation costs.
Fourth, gradual improvement in reimbursement policies lowers dual barriers for patients and technology adoption.
Reimbursement coverage expansion for transcatheter pulmonary embolectomy positively impacts markets by reducing patient out-of-pocket costs and lowering hospital financial risk for new technology adoption.
5. Unfavorable Factors for Development
First, health economic evidence compared to systemic thrombolysis remains insufficient.
While embolectomy systems may reduce major and intracranial bleeding risks compared to systemic thrombolysis, device and procedure costs are substantially higher. Whether the net benefit justifies incremental cost requires high-quality health economics research.
Second, regulatory approval processes are complex with regional variations.
Pulmonary embolectomy systems are Class III high-risk devices requiring rigorous premarket approval with evidence packages including non-clinical performance testing and clinical study data. Different regulatory standards across jurisdictions significantly increase compliance costs.
Third, strong operator technique dependence, steep learning curve, and limited talent supply.
Pulmonary embolectomy techniques differ from routine coronary interventions, requiring systematic retraining and supervised case volume accumulation, limiting rapid technology diffusion especially in regional hospitals.
Fourth, technology route disputes within the industry affect market education and clinical decision-making.
Lack of unified technical standards and divergent clinical evidence interpretations cause decision confusion for clinicians and procurement committees, sometimes shifting academic focus from whether to perform embolectomy toward which technique is better.
6. Entry Barriers
First, large-bore catheter design and manufacturing technology barriers.
Catheters must simultaneously satisfy multiple contradictory requirements. This demands substantial technical accumulation in precision extrusion, braided reinforcement, hydrophilic coating, and distal tip forming.
Second, the financial and access barriers to generating large-scale randomized controlled trial evidence.
Conducting blinded, randomized controlled trials with clinical endpoints in high and intermediate-risk pulmonary embolism patients is extremely difficult and costly, with funding requirements ranging from tens to hundreds of millions of dollars.
Third, incumbent patent portfolios and first-mover advantages.
Major products have established comprehensive intellectual property protection. New entrants must conduct thorough freedom-to-operate analyses and potential patent design-arounds while overcoming incumbent brand recognition and physician trust.
Fourth, the resource requirements for marketing channel and supply chain establishment.
Building a national or regional sales network requires substantial technical support personnel. Supply chain establishment similarly demands continuous capital and time investment.
7. Industry Chain Analysis
Upstream segment: critical raw material and core component suppliers.
This segment includes high-performance medical polymer suppliers, metal braid wire suppliers, coating material suppliers, aspiration pump manufacturers, pressure sensors, and radiopaque marker band suppliers. Supplier concentration is relatively high with limited qualified providers.
Midstream segment: embolectomy system research, development, and manufacturing enterprises.
This segment captures the industry’s core value. Participants include specialized pulmonary embolism intervention companies, large medical device companies with broad product portfolios, and CDMO service providers. Core competencies vary by enterprise type.
Downstream segment: healthcare institutions and patients.
Users are expanding from top-tier academic centers to regional general hospitals, with interventional cardiology, vascular surgery, and interventional radiology as primary users. Patient disease awareness and treatment perceptions affect the physician recommendation to patient acceptance conversion rate.
Value distribution and future trends.
High-performance medical materials upstream and embolectomy system R&D and manufacturing midstream capture highest value. Future trends include technology iteration expanding from single catheter upgrades to system-level optimization, market penetration depending primarily on training system coverage and quality, and competition shifting from product performance toward comprehensive clinical solutions.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Pulmonary Embolectomy System market is segmented as below:
By Company
Inari Medical, Inc.
Penumbra, Inc.
Boston Scientific Corporation
Medtronic plc
Teleflex Incorporated
Johnson & Johnson (Ethicon)
Terumo Corporation
Kaneka Corporation
MicroPort Scientific Corporation
Lepu Medical Technology Co., Ltd.
Avinger, Inc.
Argon Medical Devices
Control Medical Technology
Segment by Type
Large-Bore Aspiration Catheter (> 12F)
Medium-Bore Aspiration Catheter (8-12F)
Small-Bore Aspiration Catheter (< 8F)
Segment by Application
Tertiary / Academic Medical Center
Regional / Community Hospital
Specialized Cardiovascular Center
Each chapter of the report provides detailed information for readers to further understand the Pulmonary Embolectomy System market:
Chapter 1: Introduces the report scope of the Pulmonary Embolectomy System report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Pulmonary Embolectomy System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Pulmonary Embolectomy System market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Pulmonary Embolectomy System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Pulmonary Embolectomy System in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Pulmonary Embolectomy System competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Pulmonary Embolectomy System comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Pulmonary Embolectomy System market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Pulmonary Embolectomy System Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Pulmonary Embolectomy System Market Research Report 2026
Global Pulmonary Embolectomy System Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
